Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Allergan, Inc./MAP Pharmaceuticals, Inc. tender offer
| January 22, 2013 • Antitrust Risk-shifting • $958 million |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.